Galderma Pioneers Research in Injectable Aesthetics
Galderma, a leader in the dermatology sector, is at the forefront of innovative research focused on understanding how medication-driven weight loss can affect the skin. Their recent initiatives highlight the critical importance of incorporating aesthetic treatment goals into the patient journey. Galderma is also endorsing the first set of international consensus-based guidelines, developed by global experts, aimed specifically at addressing the aesthetic needs of patients utilizing weight loss medications.
New Insights from International Conferences
During the annual International Master Course on Aging Science (IMCAS) 2025 congress, Galderma plans to hold a masterclass named “Managing Facial Changes in Patients with Medication-Driven Weight Loss.” This unique event will create opportunities for esteemed aesthetics experts to share strategies for effectively managing facial changes observed in patients undergoing weight loss treatments.
Impact of Prescription Weight Loss Medications
As the prevalence of prescription weight loss medications increases, projections suggest these could generate $100 billion in sales globally by 2030. This significant uptick presents substantial implications for aesthetic practices. Notably, studies indicate that 62% of patients utilizing glucagon-like peptide-1 (GLP-1) therapy seek aesthetic treatment after consulting a healthcare professional. This statistic underscores the pressing need for guidelines that can assist healthcare providers as they navigate the unique challenges faced by this new patient demographic.
Establishing Consensus-Based Guidelines
To better support patients undergoing medication-driven weight loss, Galderma has initiated a Delphi study, focusing on the necessity for quality clinical research and developing standardized clinical guidelines. The findings from this multidisciplinary study incorporate in-depth patient interviews, extensive market research, and a review of existing literature to form a comprehensive consensus. This isn't merely a theoretical exercise; the results are rooted in real-world case studies that emphasize practical applications that healthcare providers can adopt.
Raising Awareness on Aesthetic Changes
Galderma's research highlights the aesthetic impacts of rapid weight loss, revealing that nearly 48% of participants noted significant changes to their facial appearance due to weight loss treatments. Common issues such as sagging skin, diminished facial volume, and loss of radiance are frequently reported, particularly among menopausal women. Approximately 60% of those seeking aesthetic interventions have undergone treatments specifically aimed at mitigating these adverse effects. Moreover, 33% of potential aesthetic users expressed they would have taken proactive steps to prevent skin changes had they been better informed prior to embarking on their weight loss journey.
Integration of Medical and Aesthetic Services
The recent findings emphasize a growing desire among patients to engage in dual-expertise services combining medical and aesthetic care. Over 60% of individuals undergoing medication-driven weight loss expressed interest in having integrated support throughout their aesthetic journey. This indicates a pivotal moment for healthcare professionals to broaden their approach, ensuring that the nuances of both health and aesthetic outcomes are prioritized during patient treatment planning.
Galderma's Commitment to Patient Care
Galderma continues to demonstrate its dedication to patient needs by researching and addressing the implications of medication-driven weight loss on skin health. Notably, 48% of research respondents signaled intent to engage in Sculptra treatments, with 41% interested in Restylane procedures, to cope with the changes imposed by their weight loss journey. These statistics illuminate the necessity for extended aesthetic options tailored for this unique patient population, which Galderma is ready to provide.
About Galderma
Galderma is recognized globally as a pure-play dermatology leader, operating in approximately 90 countries. The company is proud to offer a science-backed portfolio of innovative brands and services that span the dynamic dermatology market, covering injectable aesthetics, dermatological skincare, and therapeutic dermatology since its inception in 1981. Their mission is to enhance the lives of individuals by focusing on skin health and addressing consumer needs through partnerships with healthcare professionals.
Frequently Asked Questions
What is Galderma's recent research focused on?
Galderma's recent research focuses on understanding the effects of medication-driven weight loss on skin and establishing guidelines for aesthetic treatment.
What are the goals of the IMCAS 2025 masterclass?
The masterclass aims to address strategies for managing facial changes in patients undergoing medication-driven weight loss.
How does treatment choice change for patients after weight loss?
Patients often seek aesthetic interventions like Sculptra and Restylane to address facial changes resulting from weight loss treatments.
What percentage of patients desires combined healthcare services?
Over 60% of patients undergoing weight loss show a strong interest in services that combine medical and aesthetic care.
How does Galderma support healthcare providers?
Galderma provides research and guidelines to help healthcare professionals address the unique aesthetic needs of patients experiencing medication-driven weight loss.
